Intellectual Property Program ... New In Vitro Fertilization Product...Safe to Continue
. . . Intellectual Property Program - in its second agreement in what it calls its "LabChip Driven" program, Caliper Life Sciences (Nasdaq: CALP) will license its Microfuidics technology to Affymetrix (Nasdaq: AFFX), a leader in molecular biology research. The LabChip program is designed to broaden and accelerate the availability and application of its technologies.
. . . New In Vitro Fertilization Product - Halozyme Therapeutics (Amex: HTI) received FDA clearance to market Cumulase for certain in vitro fertilization procedures. Cumulase provides the IVF specialist with a safer, purer and more reliable alternative to bovine and ovine extracts that are currently used to prepare oocytes before IVF during sperm injection. Halozyme received approval in late 2004 to market Cumulase throughout the European Union. The company has a number of agreements in place to distribute Cumulase worldwide.
. . . Safe to Continue - Medicure (TSX:MPH; AMEX:MCU) received a recommendation to continue its Phase II/III MEND-CABG trial from an independent Data Safety Monitoring Board (DSMB). The Board reviewed safety data in patients who have completed 30 days of treatment following Coronary Artery Bypass Graft (CABG) surgery. The MEND-CABG clinical trial is evaluating the cardioprotective and neuroprotective effects of MC-1 in patients undergoing high-risk Coronary Artery Bypass Graft (CABG) surgery. Medicure Inc. is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine.
From: www.InvestingIN.com/biotech
. . . New In Vitro Fertilization Product - Halozyme Therapeutics (Amex: HTI) received FDA clearance to market Cumulase for certain in vitro fertilization procedures. Cumulase provides the IVF specialist with a safer, purer and more reliable alternative to bovine and ovine extracts that are currently used to prepare oocytes before IVF during sperm injection. Halozyme received approval in late 2004 to market Cumulase throughout the European Union. The company has a number of agreements in place to distribute Cumulase worldwide.
. . . Safe to Continue - Medicure (TSX:MPH; AMEX:MCU) received a recommendation to continue its Phase II/III MEND-CABG trial from an independent Data Safety Monitoring Board (DSMB). The Board reviewed safety data in patients who have completed 30 days of treatment following Coronary Artery Bypass Graft (CABG) surgery. The MEND-CABG clinical trial is evaluating the cardioprotective and neuroprotective effects of MC-1 in patients undergoing high-risk Coronary Artery Bypass Graft (CABG) surgery. Medicure Inc. is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine.
From: www.InvestingIN.com/biotech
posted by laltman at 3:32 PM
0 Comments:
Post a Comment
<< Home